Houston Methodist Research Institute nanomedicine researchers used an implantable nanofluidic device smaller than a grain of rice to deliver immunotherapy directly into a pancreatic tumor.
Credit: Houston Methodist
Taming pancreatic cancer with intratumoral immunotherapy
Houston Methodist nanomedicine researchers have found a way to tame pancreatic cancer – one of the most aggressive and difficult to treat cancers – by delivering immunotherapy directly into the tumor with a device that is smaller than a grain of rice.
In a paper recently published in Advanced Science, Houston Methodist Research Institute researchers used an implantable nanofluidic device they invented to deliver CD40 monoclonal antibodies (mAb), a promising immunotherapeutic agent, at a sustained low-dose via the nanofluidic drug-eluting seed (NDES). The result, found in murine models, was tumor reduction at a fourfold lower dosage than traditional systemic immunotherapy treatment.
“One of the most exciting findings was that even though the NDES device was only inserted in one of two tumors in the same animal model, we noted shrinkage in the tumor without the device,” said Corrine Ying Xuan Chua, Ph.D., co-corresponding author and assistant professor of nanomedicine at Houston Methodist Academic Institute. “This means that local treatment with immunotherapy was able to activate the immune response to target other tumors. In fact, one animal model remained tumor-free for the 100-days of continued observation.”
Pancreatic ductal adenocarcinoma is frequently diagnosed at advanced stages. In fact, about 85% of patients already have metastatic disease at diagnosis.
The Houston Methodist researchers are studying similar nanofluidic delivery technology on the International Space Station. Grattoni’s nanomedicine lab at Houston Methodist focuses on implantable nanofluidics-based platforms for controlled and long-term drug delivery and cell transplantation to treat chronic diseases.
Immunotherapy holds promise in treating cancers that previously did not have good treatment options. However, because immunotherapy is delivered throughout the entire body, it causes many side effects that are sometimes long-lasting, if not life-long. By focusing the delivery directly into the tumor, the body is protected from being exposed to toxic drugs and fewer side effects, essentially allowing patients undergoing treatment to have a better quality of life.
“Our goal is to transform the way cancer is treated. We see this device as a viable approach to penetrating the pancreatic tumor in a minimally invasive and effective manner, allowing for a more focused therapy using less medication,” said Alessandro Grattoni, Ph.D., co-corresponding author and chair of the Department of Nanomedicine at Houston Methodist Research Institute.
The NDES device consists of a stainless-steel drug reservoir containing nanochannels, thus creating a membrane that allows for sustained diffusion when the drug is released.
Other medical technology companies offer intratumoral drug-eluting implants for cancer therapeutics, but those are intended for shorter duration use. The Houston Methodist nanofluidic device is intended for long-term controlled and sustained release, avoiding repeated systemic treatment that often leads to adverse side effects.
Additional lab research is underway to determine the effectiveness and safety of this delivery technology, but researchers would like to see this become a viable option for cancer patients in the next five years.
Original Article: IMPLANTABLE DEVICE SHRINKS PANCREATIC TUMORS
More from: Houston Methodist Hospital
The Latest Updates from Bing News
Go deeper with Bing News on:
- Cancer Vaccines and Immunotherapy
Smyth, Lucy JC Elkord, Eyad Taher, Taher E.I. Jiang, Hui‐Rong Burt, Deborah J. Clayton, Alison van Veelen, Peter A. de Ru, Arnoud Ossendorp, Ferry Melief, Cornelis ...
- Predicting immunotherapy success via biomarkers
These findings are expected to streamline the process of matching an immunotherapy treatment to a specific patient, since it is very important to identify in advance those patients who will react ...
- Chemokine-Based Immunotherapy
Adenovirus (Ad) vectors have been used for direct intratumoral cancer immunotherapy and also delivering gene into tumor cells/DCs in order to construct the genetically modified tumor cell/DCs.
- New immunotherapy for multiple myeloma proves to be more effective in the lab than CAR-T treatment already in use
Immunotherapy is already improving treatment options for many cancer types, but research groups keep exploring ways to boost the body's immune response against the tumor. Researchers at the ...
- Clinical trial shows immunotherapy before surgery leads to promising long-term survival in sarcoma patients
Following completion of immunotherapy, all patients underwent ... The researchers found that the presence of intratumoral B cells was associated with improved OS. "Trial participant biopsies ...
Go deeper with Bing News on:
- “Here’s How I Knew I Had Pancreatic Cancer”: One Survivor’s Story After Years of Growing Clues
Pancreatic cancer, representing 3% of all cancer cases and 7% of cancer-related deaths in the US, is a serious health concern, as highlighted by the American Cancer Society. In 2024, it's projected ...
- Pancreatic Cancer Treatment: 6 Dietary Guidelines to Reduce The Risk of Deadly Disease
People diagnosed with Pancreatic cancer often find it difficult to maintain their weight and follow a healthy diet. This highly aggressive disease is rarely diagnosed at an early stage and is ...
- Pancreatic cancer survival rates improving, but doctors warn it's still tough to spot
DEIRDRE. ALL RIGHT. THANK YOU. WELL, THERE’S A NEW REPORT THAT’S OUT SHOWING THAT THE SURVIVAL RATE FOR PANCREATIC CANCER IS ON THE RISE. SO THAT’S GOOD. BUT IT STILL COMES WITH A REMINDER ...
- Amplified Sciences receives $108K Flywheel Fund investment to develop pancreatic cancer diagnostics
“We are especially excited about the potential of their plug-and-play platform to extend beyond pancreatic cancer, aiding in the early diagnosis of other diseases.” Caldwell said the Flywheel Fund ...
- Scientists discover mucus allows young pancreatic cancer cells to grow but may also prevent a deadly transformation
Knowing exactly what's inside a tumor can maximize our ability to fight cancer. But that knowledge doesn't come easy. Tumors are clusters of constantly changing cancer cells. Some become common cancer ...